

PhRMA Alliance

Biopharmaceutical Industry Commitment to Beat COVID-19

- Over 50% of PhRMA members have R&D for potential treatments and vaccines
- Collaborations with governments and diagnostic partners to increase COVID-19 testing capability and capacity. Collaboration with govt agencies and others to donate supplies and medicines.
- Screening medicines to identify potential treatments and have clinical trials underway to test therapies - clinical trial data being shared w/ government and other entities in real time
- **Expansion of our manufacturing capabilities and sharing available capacity to ramp up production once a successful medicine or vaccine is developed (repurposing both for medicine and materials)
- Integrity of the pharmaceutical supply chain remains solid and keeping our plants open to maintain a steady supply of medicines for patients
- Work w/ govt and insurers to ensure treatments/vaccines will be affordable
- Emphasis on protection of workforce- employees working from home if can

Specific CMTA Member Efforts Include (BUT NOT LIMITED TO):

Pfizer:

- Engaged in developmental screening for antiviral compounds, hoping to reach clinic by end of 2020
- In collaboration w/ BioNTech for potential first-in-class COVID-19 mRNA vaccine program, BNT162, which is expected to enter clinical testing by the end of April 2020.
- Pfizer Foundation provided a \$500,000 grant to International Medical Corps- funding supplies and support to front-line health workers
- Pfizer has committed \$40 million in medical and charitable cash grants to help combat the global health effects of COVID-19

Genentech:

- Donating \$7 million to organizations dedicated to providing emergency public health response, food assistance, housing and care

Bristol Myers Squibb:

- \$5 million in financial support and needed products has been provided to relief efforts in affected areas around the world

Merck:

- Over 500k masks donated to NYC and 300k to NJ

Novartis:

- Created \$20 million global fund to support impacted communities and entering into new collaborative research efforts such as the COVID-19 Therapeutics Accelerator
- \$5 million U.S. COVID-19 Community Response Fund for immediate response and recovery efforts
- Donating up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response

Eli Lilly:

- Lilly scientists are partnering with the Indiana State Department of Health, with support from the FDA, to accelerate testing in Indiana for SARS-CoV-2, the virus that causes COVID-19
- Also providing assistance to insulin users by covering most of the costs. Anyone who has commercial insurance or no insurance can get their monthly prescription of most Lilly insulins for \$35.

Takeda

- Takeda & CSL Behring have formed alliance w/ other leaders to develop plasmid-derived therapy for COVID-19 Investigational development of one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals with serious complications from COVID-19
- \$6.25M donation to various organizations in efforts to help those impacted by COVID-19

Johnson & Johnson:

- Will initiate human clinical studies of its lead vaccine candidate at the latest by September 2020 and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021
- Through partnership with BARDA, Johnson & Johnson together have committed more than \$1 billion of investment to co-fund vaccine research, development, and clinical testing
- \$3.7M in PPE donated
- \$250M- 10 year commitment to supporting frontline health care workers